NCT02390479

Brief Summary

The primary objective of this case-control intervention study to explore the effectiveness of non surgical periodontal therapy on the gingival crevicular fluid (GCF) levels of sclerostin in patients with chronic periodontitis (CP) so as to get a more detailed insight into its diagnostic and prognostic potential as a biomarker of periodontal disease.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P50-P75 for early_phase_1

Timeline
Completed

Started Dec 2013

Shorter than P25 for early_phase_1

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2013

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

February 18, 2015

Completed
27 days until next milestone

First Posted

Study publicly available on registry

March 17, 2015

Completed
Last Updated

September 30, 2015

Status Verified

March 1, 2015

Enrollment Period

10 months

First QC Date

February 18, 2015

Last Update Submit

September 28, 2015

Conditions

Keywords

SclerostinOPGRANKL

Outcome Measures

Primary Outcomes (1)

  • Biochemical parameters (Sclerostin levels, RANKL/OPG ratio )

    The changes in levels of sclerostin, OPG and RANKL 6 weeks after periodontal treatment determined by ELISA. The changes in levels of sclerostin were analyzed to determine diagnostic and prognostic potential as a biomarker of periodontal disease. The relative RANKL/OPG ratio (bone resorption marker) was also calculated to detect the relationship between sclerostin levels.

    Baseline and 6 weeks after treatment

Secondary Outcomes (5)

  • Probing pocket depth

    Baseline and 6 weeks after treatment

  • Probing pocket depth and clinical attachment level

    Baseline and 6 weeks after treatment

  • Gingival index

    Baseline and 6 weeks after treatment

  • Plaque index

    Baseline and 6 weeks after treatment

  • Bleeding on probing

    Baseline and 6 weeks after treatment

Study Arms (2)

Chronic periodontitis

ACTIVE COMPARATOR

GCF samples were taken before and after treatment chronic periodontitis patients. Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)

Other: non surgical periodontal treatment

clinically healthy periodontium

PLACEBO COMPARATOR

GCF samples were taken at baseline Intervention: oral hygiene instructions

Other: non surgical periodontal treatment

Interventions

1. SRP under local anaesthesia, in a total of four clinical visits 2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.

Chronic periodontitisclinically healthy periodontium

Eligibility Criteria

Age25 Years - 49 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Criteria for the healthy group were GI = 0, PPD and CAL ≤ 3 mm, and no signs of attachment and bone loss
  • Criteria for the chronic periodontitis group were clinical signs of inflammation, such as red color and swelling of the gingival margin, GI ≥ 2, PPD and CAL ≥ 5 mm with bone loss (\>30% of the existing teeth)

You may not qualify if:

  • Aggressive periodontitis, systemic diseases (i.e., diabetes mellitus, cancer, human immunodeficiency virus, bone-related diseases that compromise sclerostin, OPG or RANKL levels and collagen-metabolic diseases, or disorders), chronic high-dose steroid therapy, radiation or immunosuppressive therapy, allergy or sensitivity to any drug, pregnancy, lactation, and current smoking, smoking within the past 5 years. The individuals had no history of periodontal therapy or drug therapy (e.g. anti-inflammatory, antibiotic treatment or any other pharmacological treatment) for at least six months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

PeriodontitisSclerosteosis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NON RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Bulent Ecevit University

Study Record Dates

First Submitted

February 18, 2015

First Posted

March 17, 2015

Study Start

December 1, 2013

Primary Completion

October 1, 2014

Study Completion

October 1, 2014

Last Updated

September 30, 2015

Record last verified: 2015-03